|
|
||||||||
Section of Gastroenterology, Department of Medicine, University of Chicago, Chicago, IL 60637
The intestinal immune response to oral Ags involves a complex multistep process. The requirements for optimal intestinal T cell responses in this process are unclear. LFA-1 plays a critical role in peripheral T cell trafficking and activation, however, its role in intestinal immune responses has not been precisely defined. To dissect the role of LFA-1 in intestinal immune responses, we used a system that allows for segregation of T cell migration and activation through the adoptive transfer of LFA-1-deficient (CD18/) CD4+ T cells from DO11.10 TCR transgenic mice into wild-type BALB/c mice. We find that wild-type mice adoptively transferred with CD18/ DO11.10 CD4+ T cells demonstrate decreases in the numbers of Ag-specific T cells in the intestinal lamina propria after oral Ag administration. We also find that in addition to its role in trafficking to intestinal secondary lymphoid organs, LFA-1 is required for optimal CD4+ T cell proliferation in vivo upon oral Ag immunization. Furthermore, CD18/ DO11.10 CD4+ T cells primed in the intestinal secondary lymphoid organs demonstrate defects in up-regulation of the intestinal-specific trafficking molecules,
4
7 and CCR9. Interestingly, the defect in trafficking of CD18/ DO11.10 CD4+ T cells to the intestinal lamina propria persists even under conditions of equivalent activation and intestinal-tropic differentiation, implicating a role for CD18 in the trafficking of activated T cells into intestinal tissues independent of the earlier defects in the intestinal immune response. This argues for a complex role for CD18 in the early priming checkpoints and ultimately in the trafficking of T cells to the intestinal tissues during an intestinal immune response.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by the Crohns and Colitis Foundation of America, National Institutes of Health Grant DK02905 (to C.A.), and University of Chicago Digestive Disease Center Grant DK42086.
2 Address correspondence and reprint requests to Dr. Clara Abraham, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 6084, Chicago, IL 60637. E-mail address: cabraham{at}medicine.bsd.uchicago.edu
3 Abbreviations used in this paper: MLN, mesenteric lymph nodes; WT, wild type; DO11.10 mice, OVA-specific TCR-transgenic mice; PP, Peyers patches; PLN, peripheral lymph nodes; LPL, lamina propria lymphocytes; DC, dendritic cells; CTO, cell tracker orange; LB, large bowel; SB, small bowel.
This article has been cited by other articles:
![]() |
Y. Liang, C. Liu, J. Y. Djeu, B. Zhong, T. Peters, K. Scharffetter-Kochanek, C. Anasetti, and X.-Z. Yu 2 integrins separate graft-versus-host disease and graft-versus-leukemia effects Blood, January 15, 2008; 111(2): 954 - 962. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |